a Clinical Oncology Department , Kasr Alainy School of Medicine , Cairo , Egypt.
b Clinical Oncology Department , Ain Shams University , Cairo , Egypt.
Expert Rev Respir Med. 2019 Jun;13(6):579-584. doi: 10.1080/17476348.2019.1607300. Epub 2019 Apr 23.
: Trimodality therapy (including surgery, chemotherapy and radiation therapy) represents an important management approach of early-stage malignant pleural mesothelioma (MPM). The oncological value, as well as the proper sequence of the three modalities, is still under investigations. : The article covers the timing of chemotherapy in the management plan with either a neoadjuvant approach or adjuvant approach. It evaluates also how to select patients for induction chemotherapy and how to assess the response to treatment. : Management of patients with early-stage MPM must be completed in a multidisciplinary team in tertiary centers. Availability of newer prognostic and response assessment tools should facilitate the use of induction chemotherapy as well as the selection of patients who might benefit from radical surgery.
三联疗法（包括手术、化疗和放疗）是治疗早期恶性胸膜间皮瘤（MPM）的重要方法。这三种方法的肿瘤学价值及其合理顺序仍在研究之中。
本文涵盖了管理计划中化疗的时机，包括新辅助治疗或辅助治疗。它还评估了如何选择进行诱导化疗的患者以及如何评估治疗反应。
早期 MPM 患者的管理必须在三级中心的多学科团队中完成。新型预后和反应评估工具的应用有助于诱导化疗的应用以及选择可能从根治性手术中获益的患者。
